drugset / Trial / NCT00887965

A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab

NCT00887965

Phase 2 Completed 15 enrolled Amgen
NaSingle-groupOpen-labelSupportive care

Summary

To characterize the effects of discontinuation of denosumab therapy on variables of bone histology in postmenopausal women with low bone mass or osteoporosis. Patients who have received denosumab and completed study 20050179 (NCT00293813), completed study 20050141 (NCT00330460), completed study 20060237 (NCT00515463), completed study 20030216 (NCT00089791) but did not enroll in study 20060289 (NCT00523341) will be included in this study. Patients who will participate in the off-treatment imaging study for 20080747 (NCT00890981) are also eligible.

Timeline

Start
2009-06
Primary completion
2010-06
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Background Denosumab Monoclonal antibody